Company profile: Indaptus Therapeutics
1.1 - Company Overview
Company description
- Provider of an immunotherapy platform leveraging attenuated and killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune pathways for anti-tumor and anti-viral activity. Offers Decoy20, a Phase 1 therapeutic candidate using engineered bacteria to stimulate anti-tumor defenses, and an intravenous pipeline targeting cancers and infectious diseases with high unmet needs.
Products and services
- Proprietary Platform: Architects a gram-negative-based system utilizing attenuated and killed non-pathogenic bacteria to activate innate and adaptive cellular anti-tumor pathways with anti-viral activity
- Decoy20: Develops a clinical-stage therapeutic candidate using engineered, non-pathogenic bacteria to activate the body's immune defenses against tumors, currently progressing in Phase 1 clinical trials
- Pipeline of Therapeutic Candidates: Offers an intravenous-delivered portfolio targeting cancers and infectious diseases with high unmet medical needs, structured for systemic dosing across oncology and infectious disease indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Indaptus Therapeutics
Sanarus
HQ: United States
Website
- Description: Provider of minimally invasive devices for the diagnosis and treatment of breast tumors, including the Visica treatment system for cryoablation of breast fibroadenomas; the Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and the ImarC tissue marker system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sanarus company profile →
YM BioSciences
HQ: Canada
Website
- Description: Provider of life sciences product development services focused on identifying and advancing a diverse portfolio of cancer-related products at various stages of development, leveraging regulatory and clinical trial expertise and a diversified business model to reduce risk while advancing clinical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full YM BioSciences company profile →
Cellinfinity Bio
HQ: United States
Website
- Description: Provider of a machine-learning-driven genome editing platform and engineered cell therapies. Offers CLASH to enable precise, replicable site-specific edits across up to 20,000 genes to discover enhancements for cell therapy; HYPERBOOSTS (gain-of-function) and ENDOMODS (loss-of-function) genes; OPTI-CARS CAR design optimizations; and Supercharged Cell Therapy CAR-T and CAR-NK cells enhanced for potency, persistence, penetration, and memory against solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellinfinity Bio company profile →
Kleo Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics in development, including Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs), to treat cancer, infectious diseases, and other indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kleo Pharmaceuticals company profile →
Galecto
HQ: Denmark
Website
- Description: Provider of clinical-stage small molecule therapies for fibrosis and cancer. Develops inhibitors including GB0139, an inhaled galectin-3 inhibitor for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis; GB1211, an oral galectin-3 inhibitor for decompensated cirrhosis; and GB2064, a LOXL2 inhibitor for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galecto company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Indaptus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Indaptus Therapeutics
2.2 - Growth funds investing in similar companies to Indaptus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Indaptus Therapeutics
4.2 - Public trading comparable groups for Indaptus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →